Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced the
presentation of results from a phase 2b dose-ranging study assessing
plecanatide’s safety and efficacy in 424 adult patients (mITT
population= 423) with irritable bowel syndrome with constipation
(IBS-C). Data presented at ACG demonstrate that plecanatide, once-daily
oral tablet, significantly improved complete spontaneous bowel movement
(CSBM) frequency, bowel habits, treatment satisfaction and significantly
reduced abdominal pain in patients with IBS-C throughout the 12 week
ADTRAN ® ,
Inc. (NASDAQ:ADTN), a leading provider of next-generation networking
solutions, today announced the NetVanta® 8424 10G Multi-service Edge
Switch has achieved Metro Ethernet Forum (MEF) Carrier Ethernet 2.0
Third Quarter Summary Net income of $1.5 million compared to net income of $6.0 million in third quarter of 2013 Diluted earnings per share of $0.25 compared to diluted earnings per share of $1.27 in third quarter of 2013 Provision for loan losses of ($1.0) million, up $3.3 million from third quarter of 2013 Income tax expense of $1.1 million, up $0.9 million from third quarter of 2013 Net interest income of $4.8 million, down $0.5 million from third quarter of 2013 Non-performing assets of $13.8 million, down $2.0 million from second quarter of 2014 Year to Date Summary
ROCHESTER, Minn., Oct.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.